NYU Langone Researchers Present Breakthrough Cancer Studies at 2026 ASCO Meeting
Event summary
- NYU Langone's Perlmutter Cancer Center presented over 20 research findings at the 2026 ASCO Annual Meeting, including a phase 3 trial showing pembrolizumab reduced metastasis in rare Merkel cell carcinoma.
- A national study found lung cancer screening guidelines widened survival disparities between high- and low-income patients.
- Researchers developed a new prognostic model for metastatic castration-resistant prostate cancer that outperformed existing gene expression signatures.
- A study linked earlier immunotherapy infusion timing to lower recurrence risk in triple-negative breast cancer patients.
The big picture
NYU Langone's research presentations at the 2026 ASCO meeting highlight advancements in personalized cancer care, including immunotherapy timing, prognostic modeling, and CAR T-cell therapies. The findings underscore the need for equitable access to screening and treatment, as well as the potential for circadian biology to influence treatment outcomes. These developments come as oncology increasingly leverages data-driven approaches to improve patient stratification and care.
What we're watching
- Therapeutic Timing
- How circadian timing of immunotherapy infusions will affect treatment protocols for triple-negative breast cancer.
- Healthcare Disparities
- Whether targeted interventions can reduce the widening survival gap in lung cancer patients across income levels.
- CAR T-Cell Expansion
- The pace at which logic-gated CAR T-cell therapies advance through clinical trials for solid tumors.
Related topics